{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["Cost-utility analysis", "Hyaluronic Acid", "Intra-Articular Injections", "Knee Osteoarthritis", "Ozone Therapy", "Platelet-Rich Growth Factor", "Platelet-Rich Plasma", "QALY"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "36631861", "DateCompleted": {"Year": "2023", "Month": "01", "Day": "13"}, "DateRevised": {"Year": "2023", "Month": "01", "Day": "13"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2023", "Month": "01", "Day": "11"}], "ELocationID": ["22", "10.1186/s12891-022-06114-x"], "Journal": {"ISSN": "1471-2474", "JournalIssue": {"Volume": "24", "Issue": "1", "PubDate": {"Year": "2023", "Month": "Jan", "Day": "11"}}, "Title": "BMC musculoskeletal disorders", "ISOAbbreviation": "BMC Musculoskelet Disord"}, "ArticleTitle": "Cost-utility analysis and net monetary benefit of Platelet Rich Plasma (PRP), intra-articular injections in compared to Plasma Rich in Growth Factors (PRGF), Hyaluronic Acid (HA) and ozone in knee osteoarthritis in Iran.", "Pagination": {"StartPage": "22", "MedlinePgn": "22"}, "Abstract": {"AbstractText": ["To evaluate the cost-effectiveness of Platelet Rich Plasma (PRP), Plasma Rich in Growth Factors (PRGF), Hyaluronic Acid (HA) and ozone as effective treatment approaches in knee osteoarthritis management from Iran Health care perspective.", "A decision tree model was conducted to assess the cost-effectiveness of four common intra-articular treatment approaches in patients with mild and moderate knee osteoarthritis. The data on clinical effectiveness was obtained from a randomized controlled trial (RCT) conducted in Iran and used to estimate utility values. The direct medical costs were estimated according to tariffs for public medical centers and hospitals, approved by the Iran Ministry of Health and Medical Education in 2021. The incremental cost-effectiveness ratio (ICER) and the net monetary benefit (NMB) were used to evaluate the cost-utility analysis. Deterministic and probabilistic sensitivity analyses are performed to investigate the robustness of the results and account for the different sources of uncertainty.", "In this study, HA intra-articular injection-related costs ($581.67/patient) were defined as the highest cost, followed by PRGF ($328.10/patient), PRP (318.58/patient), and Ozone (103.20/patient). According to the utility value, PRP and PRGF (0.68) have the same and the most utility among Intra-articular injections in knee osteoarthritis management. However, the PRP injection method was identified as the most cost-effective intervention due to its high NMB and ICER estimates. Based on the Monte Carlo Simulation, PR intervention, compared to other ones, was introduced as the dominant strategy regarding knee OA management, with a WTP of $10,000 for 100% of cases.", "The study result demonstrated that intra-articular injection of PRP, compare to other injections, is a cost-effective treatment option for patients with mild and moderate knee osteoarthritis. In addition, intra-articular injection of PRP was identified as the best injection, with the highest level of net monetary benefit, for knee OA management."], "CopyrightInformation": "\u00a9 2023. The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinical Research Development Center, Shahid Modarres Hospital, Physical Medicine and Rehabilitation Research Center and Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Physical Medicine and Rehabilitation Research Center and Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}], "LastName": "Raeissadat", "ForeName": "Seyed Ahmad", "Initials": "SA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Physical Medicine and Rehabilitation Research Center and Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}], "LastName": "Rahimi", "ForeName": "Mohammad", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Physical Medicine and Rehabilitation Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}], "LastName": "Rayegani", "ForeName": "Seyed Mansoor", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran. najme.moradi@gmail.com."}], "LastName": "Moradi", "ForeName": "Najmeh", "Initials": "N"}], "PublicationTypeList": ["Randomized Controlled Trial", "Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "BMC Musculoskelet Disord", "NlmUniqueID": "100968565", "ISSNLinking": "1471-2474"}, "ChemicalList": [{"RegistryNumber": "9004-61-9", "NameOfSubstance": "Hyaluronic Acid"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Hyaluronic Acid"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Osteoarthritis, Knee"}, {"QualifierName": [], "DescriptorName": "Cost-Benefit Analysis"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Iran"}, {"QualifierName": [], "DescriptorName": "Injections, Intra-Articular"}, {"QualifierName": [], "DescriptorName": "Platelet-Rich Plasma"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}], "CoiStatement": "All authors declare that there is no conflict of interest regarding the publication of this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Contreras-Hern\u00e1ndez I, et al. Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors. Cost-Effectiveness Resource Alloc. 2008;6(1):21. doi: 10.1186/1478-7547-6-21.", "ArticleIdList": ["10.1186/1478-7547-6-21", "PMC2626578", "19014495"]}, {"Citation": "Raeissadat SA, et al. Effectiveness of intra-articular autologous-conditioned serum injection in knee osteoarthritis: a meta-analysis study. Future Science OA. 2021;7(9):FSO759. doi: 10.2144/fsoa-2021-0069.", "ArticleIdList": ["10.2144/fsoa-2021-0069", "PMC8558851", "34737891"]}, {"Citation": "Wielage RC, et al. Cost-effectiveness of duloxetine for osteoarthritis: A Quebec societal perspective. Arthritis Care Res. 2014;66(5):702\u2013708. doi: 10.1002/acr.22224.", "ArticleIdList": ["10.1002/acr.22224", "24877251"]}, {"Citation": "Rosen J, Niazi F, Dysart S. Cost-Effectiveness of Treating Early to Moderate Stage Knee Osteoarthritis with Intra-Articular Hyaluronic Acid Compared to Conservative Interventions. Adv Ther. 2020;37(1):344\u2013352. doi: 10.1007/s12325-019-01142-x.", "ArticleIdList": ["10.1007/s12325-019-01142-x", "PMC6979456", "31735982"]}, {"Citation": "Migliore A, et al. Cost-effectiveness, and budget impact analysis of viscosupplementation with Hylan GF 20 for knee and hip osteoarthritis. Clin Econ Outcomes Res. 2019;11:453. doi: 10.2147/CEOR.S194669.", "ArticleIdList": ["10.2147/CEOR.S194669", "PMC6659788", "31413608"]}, {"Citation": "Salmon J-H, et al. Cost-Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee Osteoarthritis. Pharmacoeconomics. 2018;36(11):1321\u20131331. doi: 10.1007/s40273-018-0695-5.", "ArticleIdList": ["10.1007/s40273-018-0695-5", "30047014"]}, {"Citation": "Vilchez-Cavazos F, et al. Comparison of the Clinical Effectiveness of Single Versus Multiple Injections of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis. Orthop J Sports Med. 2019;7(12):2325967119887116.", "ArticleIdList": ["PMC6918503", "31897409"]}, {"Citation": "Hermans J, et al. Cost-Utility Analysis of High Molecular Weight Hyaluronic Acid for Knee Osteoarthritis in Everyday Clinical Care in Patients at a Working Age: An Economic Evaluation of a Randomized Clinical Trial. Arthritis Care Res. 2018;70(1):89\u201397. doi: 10.1002/acr.23242.", "ArticleIdList": ["10.1002/acr.23242", "28320075"]}, {"Citation": "Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet-rich plasma) for knee osteoarthritis. World J Orthop. 2014;5(3):351. doi: 10.5312/wjo.v5.i3.351.", "ArticleIdList": ["10.5312/wjo.v5.i3.351", "PMC4095029", "25035839"]}, {"Citation": "Yu T, et al. Comparative efficacy and safety of injection therapies for knee osteoarthritis: A protocol for systematic review and Bayesian network meta-analysis. Medicine. 2020;99(47):pe22943.", "ArticleIdList": ["PMC7676524", "33217798"]}, {"Citation": "Monta\u00f1ez-Heredia E, et al. Intra-articular injections of platelet-rich plasma versus hyaluronic acid in the treatment of osteoarthritic knee pain: a randomized clinical trial in the context of the Spanish National Health Care System. Int J Mol Sci. 2016;17(7):1064. doi: 10.3390/ijms17071064.", "ArticleIdList": ["10.3390/ijms17071064", "PMC4964440", "27384560"]}, {"Citation": "Raeissadat SA, et al. An overview of platelet products (PRP, PRGF, PRF, etc.) in the Iranian studies. Future Science OA. 2017;3(4):FSO231. doi: 10.4155/fsoa-2017-0045.", "ArticleIdList": ["10.4155/fsoa-2017-0045", "PMC5674219", "29134118"]}, {"Citation": "Belzile EL, et al. Cost-utility of a single-injection combined corticosteroid-hyaluronic acid formulation vs a 2-injection regimen of sequential corticosteroid and hyaluronic acid injections. Clin Med Insights. 2017;10:1179544117712993.", "ArticleIdList": ["PMC5472395", "28638242"]}, {"Citation": "Han YH, et al. Comparison of platelet-rich plasma vs hyaluronic acid injections in patients with knee osteoarthritis: a protocol for a systematic review and meta-analysis. 2018;97(44):e13049.", "ArticleIdList": ["PMC6221718", "30383675"]}, {"Citation": "Raeissadat SA, et al. The comparison effects of intra-articular injection of Platelet Rich Plasma (PRP), Plasma Rich in Growth Factor (PRGF), Hyaluronic Acid (HA), and ozone in knee osteoarthritis; a one-year randomized clinical trial. BMC Musculoskelet Disord. 2021;22(1):1\u201314. doi: 10.1186/s12891-021-04017-x.", "ArticleIdList": ["10.1186/s12891-021-04017-x", "PMC7860007", "33536010"]}, {"Citation": "Raeissadat SA, et al. Platelet-Rich Plasma-Derived Growth Factor vs Hyaluronic Acid Injection in the Individuals with Knee Osteoarthritis: A One Year Randomized Clinical Trial. J Pain Res. 2020;13:1699. doi: 10.2147/JPR.S210715.", "ArticleIdList": ["10.2147/JPR.S210715", "PMC7354951", "32753945"]}, {"Citation": "Raeissadat SA, et al. Intra-articular ozone or hyaluronic acid injection: which one is superior in patients with knee osteoarthritis? A 6-month randomized clinical trial. J Pain Res. 2018;11:111. doi: 10.2147/JPR.S142755.", "ArticleIdList": ["10.2147/JPR.S142755", "PMC5757972", "29379312"]}, {"Citation": "Anitua E, et al. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials. 2007;28(31):4551\u20134560. doi: 10.1016/j.biomaterials.2007.06.037.", "ArticleIdList": ["10.1016/j.biomaterials.2007.06.037", "17659771"]}, {"Citation": "Raeissadat SA, et al. MRI Changes After Platelet Rich Plasma Injection in Knee Osteoarthritis (Randomized Clinical Trial) J Pain Res. 2020;13:65. doi: 10.2147/JPR.S204788.", "ArticleIdList": ["10.2147/JPR.S204788", "PMC6959502", "32021396"]}, {"Citation": "Raeissadat SA, et al. An investigation into the efficacy of intra-articular ozone (O2\u2013O3) injection in patients with knee osteoarthritis: a systematic review and meta-analysis. J Pain Res. 2018;11:2537. doi: 10.2147/JPR.S175441.", "ArticleIdList": ["10.2147/JPR.S175441", "PMC6207244", "30498370"]}, {"Citation": "Katz JN, et al. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. Osteoarthritis Cartilage. 2016;24(3):409\u2013418. doi: 10.1016/j.joca.2015.10.006.", "ArticleIdList": ["10.1016/j.joca.2015.10.006", "PMC4761310", "26525846"]}, {"Citation": "Stan G, Orban H, Orban C. Cost-effectiveness analysis of knee osteoarthritis treatment. Chirurgia. 2015;110(4):368\u2013374.", "ArticleIdList": ["26305202"]}, {"Citation": "Woods B, et al. Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. PLoS ONE. 2017;12(3):e0172749. doi: 10.1371/journal.pone.0172749.", "ArticleIdList": ["10.1371/journal.pone.0172749", "PMC5340388", "28267751"]}, {"Citation": "Rosen J, et al. Cost-effectiveness of different forms of intra-articular injections for the treatment of osteoarthritis of the knee. Adv Ther. 2016;33(6):998\u20131011. doi: 10.1007/s12325-016-0331-8.", "ArticleIdList": ["10.1007/s12325-016-0331-8", "PMC4957626", "27146676"]}, {"Citation": "Losina E, et al. Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty. Arthritis Care Res. 2015;67(2):203\u2013215. doi: 10.1002/acr.22412.", "ArticleIdList": ["10.1002/acr.22412", "PMC4422214", "25048053"]}, {"Citation": "Landi S, Landa P, Russo S. Knee OA management: a cost-effectiveness analysis of platelet-rich-plasma versus hyaluronic acid for the intra-articular treatment of knee OA in France. Int J Clin Rheumatol. 2018;13(5)."}, {"Citation": "Russo S, Landi S, Landa P. Management of knee osteoarthritis in Italy. A cost-utility analysis of Platelet-Rich-Plasma dedicated kit versus Hyaluronic acid for the intra-articular treatment of knee OA. 2017."}, {"Citation": "Samuelson EM, et al. The cost-effectiveness of platelet-rich plasma compared with hyaluronic acid injections for the treatment of knee osteoarthritis. Arthroscopy. 2020;36(12):3072\u20133078. doi: 10.1016/j.arthro.2020.07.027.", "ArticleIdList": ["10.1016/j.arthro.2020.07.027", "32721546"]}, {"Citation": "Wailoo A, Alava MH, Martinez AE. Modelling the relationship between the WOMAC osteoarthritis index and EQ-5D. Health Qual Life Outcomes. 2014;12(1):1\u20136. doi: 10.1186/1477-7525-12-37.", "ArticleIdList": ["10.1186/1477-7525-12-37", "PMC4007823", "24621311"]}, {"Citation": "Prieto L, Sacrist\u00e1n JA. Problems and solutions in calculating quality-adjusted life years (QALYs) Health Qual Life Outcomes. 2003;1(1):1\u20138. doi: 10.1186/1477-7525-1-1.", "ArticleIdList": ["10.1186/1477-7525-1-1", "PMC317370", "14687421"]}, {"Citation": "Medical Tariffs for Public Medical Centers and Hospitals, Vice-Chancellor in Treatment Affairs, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Available at: https://treatment.sbmu.ac.ir/index.jsp?pageid=69401&p=1"}, {"Citation": "Paulden M. Why it\u2019s Time to Abandon the ICER. Pharmacoeconomics. 2020;38(8):781\u201384.", "ArticleIdList": ["32390066"]}, {"Citation": "Losina E, et al. Cost-effectiveness of diet and exercise for overweight and obese patients with knee osteoarthritis. Arthritis Care Res. 2019;71(7):855\u2013864. doi: 10.1002/acr.23716.", "ArticleIdList": ["10.1002/acr.23716", "PMC6349519", "30055077"]}, {"Citation": "Oppong R, et al. Cost-effectiveness of a model consultation to support self-management in patients with osteoarthritis. Rheumatology. 2018;57(6):1056\u20131063. doi: 10.1093/rheumatology/key037.", "ArticleIdList": ["10.1093/rheumatology/key037", "PMC5965099", "29554338"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "9", "Day": "20"}, {"Year": "2022", "Month": "12", "Day": "23"}, {"Year": "2023", "Month": "1", "Day": "11", "Hour": "23", "Minute": "39"}, {"Year": "2023", "Month": "1", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "1", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "1", "Day": "11"}], "PublicationStatus": "epublish", "ArticleIdList": ["36631861", "PMC9832742", "10.1186/s12891-022-06114-x", "10.1186/s12891-022-06114-x"]}}], "PubmedBookArticle": []}